	n/N		Event rate (per 100 patients/year)		Hazard Ratio (95% CI)	P-Interaction
	Dapagliflozin	Placebo	Dapagliflozin	Placebo		
Age (years)						
≤65	30/1029	62/1052	1.7	3.5	0.48 (0.31, 0.73)	0.05
>65	55/966	64/956	3.5	4.3	0.83 (0.58, 1.19)	
Sex						
Male	67/1456	86/1455	2.8	3.7	0.79 (0.57, 1.09)	0.06
Female	18/539	40/533	1.9	4.4	0.43 (0.25, 0.75)	
Race						
White	60/1291	84/1302	2.7	3.8	0.71 (0.51, 0.99)	0.91
Black	5/78	9/74	3.9	7.9	NC	
Asian	19/579	31/581	2.2	3.6	0.61 (0.34, 1.08)	
Other	1/47	2/51	1.1	2.0	NC	
Glycaemic status						
Pre-diabetes	81/1189	118/1219	4.2	6.2	0.69 (0.52, 0.91)	0.58
Normoglycaemic	4/806	8/789	0.3	0.6	NC	
Baseline eGFR (mL/min/1.73m^2)						
<30	2/107	5/124	0.9	2.1	NC	0.48
30-<45	24/499	25/465	2.7	3.1	0.88 (0.50, 1.54)	
45-60	29/516	39/525	3.4	4.4	0.75 (0.46, 1.21)	
≥60	30/872	57/893	2.2	4.3	0.52 (0.34, 0.81)	
Systolic blood pressure (mmHg)						
<130	60/1263	73/1283	3.0	3.7	0.84 (0.59, 1.18)	0.04
≥130	25/732	53/725	1.9	4.1	0.45 (0.28, 0.73)	
Body mass index (kg/m^2)						
<30	58/1397	70/1388	2.6	3.2	0.82 (0.58, 1.16)	0.08
≥30	27/595	56/620	2.6	5.2	0.49 (0.31, 0.78)	
Coronary heart disease						
Yes	48/804	66/826	3.9	5.3	0.73 (0,50, 1.06)	0.44
No	37/1191	60/1182	1.8	3.0	0.59 (0.39, 0.89)	
Statins at baseline						
Yes	60/1143	85/1176	3.1	4.5	0.71 (0.51, 0.99)	0.57
No	25/852	41/832	1.8	3.0	0.60 (0.37, 0.99)	
Beta-blockers at baseline						
Yes	72/1459	104/1145	3.2	4.8	0.68 (0.50, 0.91)	0.77
No	13/536	22/563	1.2	2.0	0.60 (0.30, 1.20)	
Loop diuretics at baseline						
Yes	56/1098	95/1130	3.4	5.7	0.60 (0.43, 0.83)	0.17
No	29/897	31/878	1.8	1.9	0.90 (0.54, 1.50)	
Thiazide at baseline						
Yes	12/213	12/220	3.2	3.2	1.06 (0.47, 2.36)	0.24
No	73/1782	114/1788	2.5	4.0	0.63 (0.47, 0.84)